Evaluation Of A Financial Incentive To Improve The Use Of Preventive Medicines By People With Asthma
Funder
National Health and Medical Research Council
Funding Amount
$137,860.00
Summary
Rising costs are threatening the future viability of the Pharmaceutical Benefits Scheme. New approaches are needed to address this challenge, including developing financial incentives for consumers to use effective low cost medicines in preference to higher cost alternatives. This study will develop a consumer incentive for use of low cost asthma preventer medicines, model the economic effects of this and bring together stakeholders to examine the policy and practice changes needed to implement ....Rising costs are threatening the future viability of the Pharmaceutical Benefits Scheme. New approaches are needed to address this challenge, including developing financial incentives for consumers to use effective low cost medicines in preference to higher cost alternatives. This study will develop a consumer incentive for use of low cost asthma preventer medicines, model the economic effects of this and bring together stakeholders to examine the policy and practice changes needed to implement the incentive.Read moreRead less
Developing An Australian Valuation For The EQ-5D-5L Quality Of Life Instrument
Funder
National Health and Medical Research Council
Funding Amount
$348,357.00
Summary
In the assessment of gains resulting from a health technology, it is standard to consider both mortality and quality of life effects. This project explores how Australians value different components of quality of life. To do this, we are running an online survey called a discrete choice experiment, and analysing the data using a range of cutting-edge econometric techniques. This will allow policy-makers to better reflect people's preferences when making decisions about new technologies.
Pregabalin In Addition To Usual Care For Sciatica (PRECISE): A Randomised, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$638,663.00
Summary
Sciatica is a severe and disabling form of back pain that is characterised by radiating pain down the leg. However there is little evidence on how best to treat it conservatively. We propose to investigate the effectiveness of pregabalin, a medication that specifically targets sciatic pain, in addition to usual care in 204 patients with sciatica. We hypothesise that adding pregabalin will be more effective in reducing the severity of leg pain.
Discovery Early Career Researcher Award - Grant ID: DE240100168
Funder
Australian Research Council
Funding Amount
$413,847.00
Summary
Self-Supervised Sequential Biomedical Image-Omics. This project aims to develop a self-supervised sequential biomedical image-omics model to uncover the underlying biological processes e.g., normal or abnormal. Sequential biomedical images are state-of-the-art imaging modalities which allow to depict changes in progression to the human body. New self-supervised machine learning algorithms are proposed to derive features from heterogenous and unlabelled sequential images. These derived features w ....Self-Supervised Sequential Biomedical Image-Omics. This project aims to develop a self-supervised sequential biomedical image-omics model to uncover the underlying biological processes e.g., normal or abnormal. Sequential biomedical images are state-of-the-art imaging modalities which allow to depict changes in progression to the human body. New self-supervised machine learning algorithms are proposed to derive features from heterogenous and unlabelled sequential images. These derived features will then be used to characterise the morphological and functional changes, which provide opportunities to increase understanding of progression of diseases of individual subject. The outcome from this project will provide new insights into system biology with potential future benefits in healthcare.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE240100987
Funder
Australian Research Council
Funding Amount
$402,287.00
Summary
Multifunctional polymers for combined algal inactivation and flocculation. Algal cells are harmful because they produce toxins and other undesirable metabolites. So, they are killed, aggregated, and separated from the water in distinct steps. Cell killing and aggregation are achieved via chemical dosing, which damages the cells and releases undesirable compounds. The aim is to develop multifunctional polymers that can simultaneously kill and aggregate the cells without causing cell damage. Addit ....Multifunctional polymers for combined algal inactivation and flocculation. Algal cells are harmful because they produce toxins and other undesirable metabolites. So, they are killed, aggregated, and separated from the water in distinct steps. Cell killing and aggregation are achieved via chemical dosing, which damages the cells and releases undesirable compounds. The aim is to develop multifunctional polymers that can simultaneously kill and aggregate the cells without causing cell damage. Additionally, this project provides insight into the mechanisms of polymer-induced cell damage and death that will be used to improve existing treatment methods. By combining treatment steps, chemical demand and costs will decrease, while there will be an increase in sustainability and benefits to the Australian water industry.Read moreRead less
Rapidly giving intravenous fluid to prevent or treat shock (fluid resuscitation) is one of the commonest treatments given to critically ill patients. Current guidelines recommend crystalloid solutions but it is unknown whether any particular crystalloid is better than others. This trial will determine whether the use of one of two crystalloid fluids, saline or PlasmaLyte, reduces the risk of organ injuries, such as kidney failure, and improves patients chances of surviving critically illness.
Estimating The Burden Of Group A Streptococcal Diseases In Victoria
Funder
National Health and Medical Research Council
Funding Amount
$386,760.00
Summary
Despite the considerable advances in the diagnosis and treatment of group A streptococcal (GAS) diseases made during the last century, the impressive spectrum of infections caused by this organism continues to have a significant impact in developed countries. This spectrum includes diseases that are mild but common (e.g. sore throat, skin sores), rare but very severe (e.g. bloodstream infections, flesh-eating bacteria) and those that are more common in developing countries and the Aboriginal pop ....Despite the considerable advances in the diagnosis and treatment of group A streptococcal (GAS) diseases made during the last century, the impressive spectrum of infections caused by this organism continues to have a significant impact in developed countries. This spectrum includes diseases that are mild but common (e.g. sore throat, skin sores), rare but very severe (e.g. bloodstream infections, flesh-eating bacteria) and those that are more common in developing countries and the Aboriginal population (e.g. rheumatic fever, kidney disease). Streptococcal sore throat remains one of the most common childhood infections, and severe group A streptococcal diseases are thought to be increasing in incidence in Australia. Yet, there are no accurate data on the incidence and costs of these or other GAS diseases in non-Aboriginal Australians, or in most other populations around the world. It is becoming more urgent to collect this data as numerous vaccine candidates are entering human trials, new approaches to the treatment of sore throat are emerging, and new strategies to treat and control the spread of severe disease are being developed. We propose a comprehensive strategy to measure the incidence, prevalence and costs of each group of GAS diseases. We will follow a group of families for 12 months to detect cases of GAS sore throat and skin sores and measure the impact on the family. We will survey children in schools to estimate the prevalence of skin sores. We will check hospital records to calculate the number of cases of rheumatic fever and kidney disease. And we will maintain surveillance for severe diseases by checking hospital and laboratory records. We will also check to see if family members of people with severe disease have the GAS bacterium in their throats. We will then compile these data into a comprehensive estimate of the burden of disease in Victoria, and estimate the cost-effectiveness of different treatment and prevention strategies.Read moreRead less
Advanced Heart Failure Management With Ventricular Assist Therapy – Evaluating Australian Costs Of Care And Effectiveness From Implant To Transplant Or End Of Life
Funder
National Health and Medical Research Council
Funding Amount
$45,668.00
Summary
Ventricular Assist Devices (VADs) are implantable heart pumps that are increasingly being used to slow down the progression of end stage heart failure. This project assesses the costs and effectiveness of VAD therapy and advanced heart failure medical management in an Australian health care setting. The aim is to provide Australian clinicians and health decision makers access to current and relevant, clinical, cost and effectiveness data for advanced heart failure and VAD therapy.
Special Research Initiatives - Grant ID: SR180100027
Funder
Australian Research Council
Funding Amount
$1,086,676.00
Summary
Integrated, scalable technology solutions for PFAS removal and destruction. This project aims to deliver a ready-to-deploy and scalable modular technology that is capable of removing poly- and per-fluoroalkyl substances (PFAS) from a variety of water sources, including groundwater and surface waters, to make them virtually PFAS-free and therefore safe for human consumption. The concept draws on recent advances in water treatment and electrochemistry that is based on ion exchange, nanofiltration ....Integrated, scalable technology solutions for PFAS removal and destruction. This project aims to deliver a ready-to-deploy and scalable modular technology that is capable of removing poly- and per-fluoroalkyl substances (PFAS) from a variety of water sources, including groundwater and surface waters, to make them virtually PFAS-free and therefore safe for human consumption. The concept draws on recent advances in water treatment and electrochemistry that is based on ion exchange, nanofiltration and advanced oxidation. A risk-based framework will be developed to deliver fit-for-purpose solutions at minimal cost for stakeholders and taxpayers. This project is expected to benefit the residents who live in the vicinity of contaminated waterways or consume water from polluted sources.Read moreRead less
REACH: Researching Effective Approaches To Cleaning In Hospitals
Funder
National Health and Medical Research Council
Funding Amount
$657,862.00
Summary
Healthcare associated infections are a major challenge for hospitals. Infections can spread via the patient environment, because colonized patients and staff can contaminate surfaces and equipment with micro-organisms. Cleaning is a vital component of patient care, but is a complex process with little real evidence to inform practice. This project will take a targeted approach to improving hospital cleaning to reduce infection rates; and examine the cost-effectiveness of this approach.